Background: The clinical impact of acute vasoreactivity testing with inhaled nitric oxide (NO testing) in severe pulmonary hypertension associated with lung disease (LD-PH) remains unknown.
Methods: We retrospectively reviewed 48 consecutive patients with severe LD-PH (73 ± 9 years; male: 81%) who underwent NO testing between 2014 and 2022. We conducted an exploratory analysis of the association between the response to NO testing and both the efficacy of pulmonary vasodilators and prognosis.
Results: NO testing demonstrated a significant improvement in hemodynamics, with an average reduction of 1.8 wood units in pulmonary vascular resistance (PVR) without a decrease of oxygen saturation. Patients were divided into the vasoreactive and non-vasoreactive groups based on the median PVR response (-15%) to NO testing. The vasoreactive group had a higher proportion of patients who initiated pulmonary vasodilators and had better long-term prognosis than that of the non-vasoreactive group (P = 0.03). Among the 36 patients (75%) who initiated pulmonary vasodilators after NO testing, the vasoreactive group demonstrated a significant improvement in the symptom, brain natriuretic peptide level, and hemodynamics at the first follow-up (median 4 months), whereas the non-vasoreactive group did not. Moreover, a correlation was observed between the change in PVR at NO testing and the change in PVR after initiation of pulmonary vasodilators (r = 0.42, P = 0.02).
Conclusions: The PVR response to NO testing associated with short-term efficacy of pulmonary vasodilators in patients with severe LD-PH. Prospective studies of PVR response to NO testing on the clinical efficacy in large-scale LD-PH cohorts are warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.resinv.2025.02.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of mA modification during macrophage metabolic reprogramming in human diseases and animal models.
Front Immunol
March 2025
Department of Laboratory Medicine, Jiangsu Province Engineering Research Center for Precise Diagnosis and Treatment of Inflammatory Diseases, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Macrophage metabolic reprogramming refers to the process by which macrophages adjust their physiological pathways to meet survival and functional demands in different immune microenvironments. This involves a range of metabolic pathways, including glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, fatty acid oxidation, and cholesterol transport. By modulating the expression and activity of key enzymes and molecules within these pathways, macrophages can make the transition between pro- and anti-inflammatory phenotypes, thereby linking metabolic reprogramming to inflammatory responses and the progression of several diseases, such as atherosclerosis, inflammatory bowel disease (IBD), and acute lung injury (ALI).
View Article and Find Full Text PDFPulmonary Artery Denervation for Medication Refractory Pulmonary Hypertension (PARPH Study) - Study Protocol for a Prospective, Open-Label, Single-Arm Clinical Trial.
Circ Rep
March 2025
Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center Osaka Japan.
Background: Despite the development of effective pulmonary vasodilators, the prognosis for patients with pulmonary hypertension (PH) remains poor, particularly in medication-refractory patients. Catheter-based pulmonary artery denervation (PADN) is an emerging therapeutic strategy targeting the sympathetic nervous system in various types of PH. However, data on its safety and efficacy in refractory patients with PH who truly require non-pharmacotherapy are lacking.
View Article and Find Full Text PDFComparison of usability and user-friendliness of three FeNO analyzers in a general population cohort of the LEAD study.
Sci Rep
March 2025
Ludwig Boltzmann Institute for Lung Health, Pavillon Hermann, 3rd Floor, Sanatoriumstreet 2, 1140, Vienna, Austria.
Exhaled nitric oxide (FeNO) is a marker for airway inflammation measured by hand-held or stationary analyzers, but their usability was not previously assessed. NIOX VERO (CN), NObreath (BN), Vivatmo pro (BV), and CLD88 analyzer (reference, EC) were compared in a prospective study of the general population LEAD (Lung, hEart, sociAl, boDy) cohort, including the System Usability Scale and tests for equivalence at a clinically relevant range of ≤ 70 ppb with linear models and Bland-Altman plots. In 486 participants (62.
View Article and Find Full Text PDFHemodynamic phenotypes in congenital diaphragmatic hernia and their association with morbidity and mortality.
Bol Med Hosp Infant Mex
March 2025
Clinical Research Service, Hospital Infantil de México Federico Gómez, Mexico City. Mexico.
Background: Congenital diaphragmatic hernia (CDH) is a severe condition associated with high morbidity and mortality. Its severity correlates with the degree of pulmonary hypoplasia. Recent literature has emphasized the importance of identifying distinct hemodynamic phenotypes (HP) to guide physiology-based management.
View Article and Find Full Text PDFRationale: Physiological responses to hypoxia involve adaptations in the hematopoietic and cardiovascular systems, which work together to ensure adequate oxygen delivery to tissues for energy production. The arginine/nitric oxide (NO) pathway regulates both systems through its effects on erythropoiesis and vasodilation. In Tibetan populations native to high-altitude hypoxia, increased NO production from arginine and decreased arginine metabolism by arginase contribute to these adaptive mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!